Literature DB >> 17923468

Exercise-induced systolic dysfunction in patients with non-obstructive hypertrophic cardiomyopathy and mutations in the cardiac troponin genes.

K Sakata1, H Ino, N Fujino, M Nagata, K Uchiyama, K Hayashi, T Konno, M Inoue, H Kato, Y Sakamoto, T Tsubokawa, M Yamagishi.   

Abstract

OBJECTIVES: The aim of this study was to investigate left ventricular (LV) function reserve in hypertrophic cardiomyopathy (HCM) patients with and without cardiac troponin gene mutations before transition to the dilated phase.
METHODS: LV ejection fraction (EF) was continuously evaluated in 52 patients with non-obstructive HCM during supine ergometer exercise using radionuclide ventricular function monitoring with a cadmium telluride detector (VEST). On the basis of genetic analysis, patients were divided into two groups: 10 with cardiac troponin gene mutations (group A) and 42 without these gene mutations (group B).
RESULTS: Exercise duration, peak exercise load, and heart rate during exercise did not differ between the two groups. The differences from baseline to peak exercise ofthe LV end-diastolic volume decreased similarly in the twogroups. In contrast, the difference of the LV end-systolicvolume in group A increased significantly compared withgroup B (17.7% (SD 12.7%) vs 3.4% (SD 13.2%);p=0.0031). Consequently, the difference of LVEF ingroup A decreased significantly in contrast with group B(-14.1% (SD 11.1%) vs -1.2% (SD 11.7%); p=0.0025).Additionally, the changes in LVEF and stroke volumedecreased significantly more in group A than in group B(-22.2% (SD 18.6%) vs -1.1% (SD 17.8%); p=0.0017and -12.9% (SD 21.7%) vs 12.3% (SD 24.4%);p=0.0042, respectively).
CONCLUSIONS: These results suggest that HCM patientswith cardiac troponin gene mutations may displayexercise-induced LV systolic dysfunction more frequentlythan HCM patients without this abnormality

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17923468     DOI: 10.1136/hrt.2007.116970

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  7 in total

1.  Exercise in hypertrophic cardiomyopathy.

Authors:  Sharlene M Day
Journal:  J Cardiovasc Transl Res       Date:  2009-10-14       Impact factor: 4.132

Review 2.  Myocardial energy depletion and dynamic systolic dysfunction in hypertrophic cardiomyopathy.

Authors:  Julian O M Ormerod; Michael P Frenneaux; Mark V Sherrid
Journal:  Nat Rev Cardiol       Date:  2016-07-14       Impact factor: 32.419

3.  Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy.

Authors:  Mark Luedde; Ulrich Flögel; Maike Knorr; Christina Grundt; Hans-Joerg Hippe; Benedikt Brors; Derk Frank; Uta Haselmann; Claude Antony; Mirko Voelkers; Juergen Schrader; Patrick Most; Bjoern Lemmer; Hugo A Katus; Norbert Frey
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

4.  Abnormal blood pressure response to exercise occurs more frequently in hypertrophic cardiomyopathy patients with the R92W troponin T mutation than in those with myosin mutations.

Authors:  Marshall Heradien; Miriam Revera; Lize van der Merwe; Althea Goosen; Valerie A Corfield; Paul A Brink; Bongani M Mayosi; Johanna C Moolman-Smook
Journal:  Heart Rhythm       Date:  2009-09-01       Impact factor: 6.343

5.  Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.

Authors:  Noboru Fujino; Tetsuo Konno; Kenshi Hayashi; Akihiko Hodatsu; Takashi Fujita; Toyonobu Tsuda; Yoji Nagata; Masa-aki Kawashiri; Hidekazu Ino; Masakazu Yamagishi
Journal:  Clin Cardiol       Date:  2012-11-29       Impact factor: 2.882

Review 6.  Familial dilated cardiomyopathy: Current challenges and future directions.

Authors:  Diane Fatkin
Journal:  Glob Cardiol Sci Pract       Date:  2012-08-27

7.  Characterisation of LV myocardial exercise function by 2-D strain deformation imaging in elite adolescent footballers.

Authors:  Guido E Pieles; Lucy Gowing; Diane Ryding; Dave Perry; Steven R McNally; A Graham Stuart; Craig A Williams
Journal:  Eur J Appl Physiol       Date:  2020-10-08       Impact factor: 3.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.